Levocarb-Gry

Levodopa/Carbidopa, the active ingredient in Levocarb-Gry, is a dopamine precursor/DOPA decarboxylase inhibitor combination presented as an oral tablet for oral use. It treats Parkinson's disease and Parkinsonian syndrome in adults.

GNH USA supplies Levocarb-Gry as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levocarb-Gry acts on the dopaminergic pathway to manage movement disorders associated with Parkinsonism. - Parkinson's disease: improves motor symptoms such as tremor, rigidity and bradykinesia. - Parkinsonian syndrome: alleviates rigidity and gait disturbances. - Levodopa‑responsive Parkinsonism: restores dopaminergic activity to reduce motor fluctuations.

Levocarb-Gry may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Vomiting - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or psychosis - Severe allergic reactions (e.g., rash, angioedema)

When prescribing Levocarb-Gry, clinicians should consider several safety measures. - Dose titration: start low and increase gradually to minimize adverse effects. - Monitor blood pressure: risk of orthostatic hypotension, especially in the elderly. - Assess liver and kidney function: adjust dosing if organ impairment is present. - Avoid abrupt discontinuation: sudden stop may worsen Parkinsonian symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Levocarb-Gry can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO‑B inhibitors: risk of hypertensive crisis. - Non‑selective MAO inhibitors: severe hypertension. - Antipsychotics (e.g., haloperidol): reduce levodopa efficacy. - Antihypertensives: additive hypotensive effect.

Moderate Interactions (Monitor Closely): - SSRIs/SNRIs: may increase serotonin syndrome risk. - Iron supplements: reduce levodopa absorption. - High‑protein meals: decrease levodopa bioavailability.